AbbVie | ABBV

Stock Price
160.70
Daily Change
4.56 2.92%
Monthly
-0.80%
Yearly
20.43%
Q2 Forecast
162.62
Peers Price Chg Day Year Date
Eisai 6,753.00 178.00 2.71% -25.38% May/31
AbbVie 160.70 4.56 2.92% 20.43% May/31
Abbott 102.25 0.40 0.39% -0.55% May/31
ALKERMES 23.40 0.19 0.82% -20.08% May/31
Amgen 305.48 4.54 1.51% 42.57% May/31
AstraZeneca 12,190.00 162.00 1.35% 4.46% May/31
Biogen 224.97 5.08 2.31% -25.61% May/31
BioMarin Pharmaceutical 75.07 0.59 0.79% -14.94% May/31
Bristol-Myers Squibb 41.14 0.88 2.19% -36.39% May/31
Gilead Sciences 64.00 0.13 0.20% -16.02% May/31
GlaxoSmithKline 1,766.50 36.50 2.11% 31.08% May/31
J&J 146.71 1.47 1.01% -5.07% May/31
Eli Lilly 820.34 7.42 0.91% 87.94% May/31
Medtronic 81.37 0.79 0.98% -1.67% May/31
Merck 125.59 1.02 0.82% 13.22% May/31
Neurocrine Biosciences 135.41 -1.25 -0.91% 48.49% May/31
Novartis 92.96 1.73 1.90% 5.56% May/31
Pacira 30.33 -0.13 -0.43% -20.27% May/31
Pfizer 28.70 0.43 1.53% -24.51% May/31
Perrigo 27.54 0.04 0.13% -14.10% May/31
Ultragenyx Pharmaceutical 40.14 1.49 3.86% -19.09% May/31
Regeneron Pharmaceuticals 980.16 8.27 0.85% 34.05% May/31
Roche Holding 231.00 2.70 1.18% -20.28% May/31
Sanofi 89.76 1.19 1.34% -4.72% May/31
UCB 128.65 2.15 1.70% 59.18% May/31
United Therapeutics 275.13 4.68 1.73% 28.88% May/31
Vertex Pharmaceuticals 454.94 11.98 2.70% 40.58% May/31
Zoetis 169.75 0.57 0.34% 2.26% May/31

Indexes Price Day Year Date
US500 5278 42.03 0.80% 25.03% May/31

AbbVie traded at $160.70 this Friday May 31st, increasing $4.56 or 2.92 percent since the previous trading session. Looking back, over the last four weeks, AbbVie gained 0.80 percent. Over the last 12 months, its price rose by 20.43 percent. Looking ahead, we forecast AbbVie to be priced at 162.62 by the end of this quarter and at 157.93 in one year, according to Trading Economics global macro models projections and analysts expectations.

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.